| scholarly article | Q13442814 |
| P50 | author | Henriëtte M.G. Willems | Q52116793 |
| Gillian Farnie | Q55345647 | ||
| John Lunec | Q90706188 | ||
| P2093 | author name string | Bernard T Golding | |
| Per Källblad | |||
| K Saravanan | |||
| David R Newell | |||
| Roger J Griffin | |||
| Ian R Hardcastle | |||
| Shafiq U Ahmed | |||
| Stefano Norbedo | |||
| Helen Atkins | |||
| Julian S Northen | |||
| Stuart J Kemp | |||
| Rebecca J Reid | |||
| Claire Hutton | |||
| Henriëtte M G Willems | |||
| Martin S Kitching | |||
| Sabrina Guyenne | |||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | protein-protein interaction | Q896177 |
| P304 | page(s) | 6209-6221 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold | |
| P478 | volume | 49 |
| Q86826027 | A computational analysis of binding modes and conformation changes of MDM2 induced by p53 and inhibitor bindings |
| Q48184446 | Antitumor evaluation and 3D-QSAR studies of a new series of the spiropyrroloquinoline isoindolinone/aza-isoindolinone derivatives by comparative molecular field analysis (CoMFA). |
| Q58738105 | Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors |
| Q26749008 | Chemical Variations on the p53 Reactivation Theme |
| Q38029143 | De novo design: balancing novelty and confined chemical space |
| Q30670705 | Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions†Electronic supplementary information (ESI) available: Experimental details for compound synthesis, analytical data for all compounds and in |
| Q51560838 | Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer. |
| Q26827810 | Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. |
| Q37305306 | Identification and molecular genetic analysis of the cichorine gene cluster in Aspergillus nidulans. |
| Q84959295 | Inhibition of protein-protein interactions with low molecular weight compounds |
| Q37855826 | Inhibitors of MDM2 and MDMX: a structural perspective. |
| Q38865504 | Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction. |
| Q90292991 | Nonselective Chemical Inhibition of Sec7 Domain-Containing ARF GTPase Exchange Factors |
| Q37944599 | Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma |
| Q98185086 | Potency and selectivity optimization of tryptophanol-derived oxazoloisoindolinones: novel p53 activators in human colorectal cancer |
| Q37483244 | Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction |
| Q36329555 | Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation |
| Q51453546 | QSAR models for isoindolinone-based p53-MDM2 interaction inhibitors using linear and non-linear statistical methods. |
| Q39205536 | Reviving the guardian of the genome: Small molecule activators of p53. |
| Q64236652 | Roles of computational modelling in understanding p53 structure, biology, and its therapeutic targeting |
| Q35411745 | Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach |
| Q37806669 | Small-Molecule Inhibitors of the p53-MDM2 Interaction |
| Q98894841 | Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives |
| Q35087851 | Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. |
| Q39036213 | Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy |
| Q47588107 | Structural determinants of benzodiazepinedione/peptide-based p53-HDM2 inhibitors using 3D-QSAR, docking and molecular dynamics |
| Q38987994 | Synthesis of spiro[isoindole-1,5'-isoxazolidin]-3(2H)-ones as potential inhibitors of the MDM2-p53 interaction. |
| Q40854245 | TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation |
| Q41056546 | Tandem C(sp3)-H Arylation/Oxidation and Arylation/Allylic Substitution of Isoindolinones |
| Q33334544 | Tandem driven dynamic combinatorial resolution via Henry-iminolactone rearrangement |
| Q37068706 | Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? |
| Q38247168 | Targeting p53-MDM2-MDMX loop for cancer therapy |
| Q37260683 | Targeting the p53 pathway |
| Q35795073 | Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils |
| Q27685287 | The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant |
| Q30380490 | Therapeutic considerations for Mdm2: not just a one trick pony |
| Q35708113 | Translational approaches targeting the p53 pathway for anti-cancer therapy |
| Q39606430 | Understanding small-molecule binding to MDM2: insights into structural effects of isoindolinone inhibitors from NMR spectroscopy |
| Q41830943 | Unprecedented selective homogeneous cobalt-catalysed reductive alkoxylation of cyclic imides under mild conditions. |
Search more.